摘要
目的探讨贝伐珠单抗对肝癌细胞HepG2血管内皮生长因子(vascular endothelial growth factor,VEGF)相关受体的影响。方法通过不同浓度的贝伐珠单抗降低培养液中VEGF来模拟低浓度VEGF的肿瘤微环境,RT-PCR、ELISA、Western blotting检测肿瘤细胞VEGF相关受体表达水平的变化。结果细胞培养液的VEGF浓度大幅度下降(P<0.05);可溶性VEGFR2的浓度出现了上升(P<0.05);HepG2细胞VEGF和VEGFR1表达水平无明显变化(P>0.05);VEGFR2表达水平出现了明显的上调(P<0.05)。结论贝伐珠单抗导致了肝癌细胞HepG2大幅度上调了VEGFR2的表达。
Objective To study the role of bevacizumab in up-regulation of VEGFR2 expression in HepG2 cells. Methods Tumor microenvironment was simulated by decreasing the VEGF concentration with bevacizumab monoantibody. Expression of VEGF2 in HepG2 cells was detected by RT-PCR, ELISA and Western blot, respectively. Results The VEGF concentration was significantly decreased （P 〈 0.05） and the soluble VEGFR2 concentration was significantly increased in medium （P 〈 0.05）. No significant change occurred in the VEGF and VEGFR1 expression level （P 〉 0.05） whereas the expression of VEGFR2 was significantly upregulated in HepG2 cells （P 〈 0.05）. Conclusion Bevacizumab up-regulates the expression of VEGF2 in HepG2 cells.
出处
《解放军医学院学报》
CAS
2014年第5期474-476,488,共4页
Academic Journal of Chinese PLA Medical School
基金
北京科委首都医疗特色项目(2131107002213040)~~
